Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Cytologic findings in effusions from patients with SARS-CoV-2 infection

Richard L. Cantley, MD*, Steven Hrycaj, PhD, Kristine Konopka, MD, May P. Chan, MD, Tao Huang, MD, Liron Pantanowitz, MD

Department of Pathology, University of Michigan-Michigan Medicine, Ann Arbor, Michigan

Received 7 December 2020; received in revised form 15 January 2021; accepted 18 January 2021

KEYWORDS
Body cavity fluid; COVID-19; Cytology; Effusion; Pericardial fluid; Pleural fluid; SARS-CoV-2

Introduction Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with “flu-like” upper respiratory tract symptoms and pneumonia. Body cavity effusions develop in a subset of patients with advanced disease. Although SARS-CoV-2 is known to be present in certain body fluids (eg, blood) of COVID patients, it remains unclear if body cavity fluids are sites of infection. Our aim was to characterize the cytologic and clinical findings in COVID-19 patients with effusions.

Materials and methods A record search for all cases of body cavity effusion cytology in SARS-CoV-2 positive patients from March 1, 2020, to September 1, 2020, was performed. Clinical history, fluid chemical analysis, cytologic findings, and patient outcomes were recorded. All cytology slides were reviewed. In situ hybridization (ISH) targeting SARS-CoV-2 spike protein transcript (V-nCoV2019-S) was performed on cell block material in all cases.

Results A total of 17 effusion cytology cases were identified among 15 COVID patients, including 13 pleural, 2 pericardial, and 2 peritoneal. Most (13 of 15) patients were hospitalized for COVID complications. Eight patients died during hospitalization, 7 from COVID complications. All fluids were transudative by protein criteria. Lymphocytic or histiocytic inflammation predominated in 12 of 17 cases. Five exhibited hemophagocytosis. No viral cytopathic changes or extra-medullary megakaryocytes were seen. Viral RNA was not detected in any case by ISH.

Conclusions Body cavity effusion is an ominous finding in patients with advanced COVID-19 disease. Such effusions tend to be transudative with lymphohistiocytic inflammation, and commonly exhibit hemophagocytosis, an otherwise rare finding in effusion cytologies. No direct infection of cellular elements by SARS-CoV-2 was identified by ISH.

© 2021 Published by Elsevier Inc. on behalf of American Society of Cytopathology.
Introduction

Severe acute respiratory syndrome coronavirus (SARS-CoV-2) is a novel RNA coronavirus that is the underlying cause of coronavirus disease 2019 (COVID-19), which the World Health Organization declared a pandemic in March 2020. The symptoms of COVID-19 are variable and non-specific. The majority of patients infected with SARS-CoV-2 are asymptomatic or develop mild “flu-like” symptoms such as cough, fever, and fatigue. However, a portion of patients (~10%) develop more severe respiratory disease, including interstitial pneumonia and acute respiratory distress syndrome, as well as multiple organ dysfunction/failure. Severe cases of COVID have been linked to abundant release of proinflammatory cytokines, resulting in a so-called cytokine storm and hemophagocytic syndrome, a hyperactive autoimmune inflammatory immune response that leads to tissue recruitment of T-cells, neutrophils, and macrophages with resulting end-organ damage.

Chest radiographic findings in COVID-19 are typically non-specific. Common computed tomography (CT) findings include ground-glass opacities, often with consolidation, typically in a bilateral and peripheral distribution. Body cavity effusions are relatively uncommon but are identifiable on CT imaging in a subset of COVID-19 patients, with pleural effusion present in 5.88% and pericardial effusion in 4.55% of cases in 1 meta-analysis. Pleural effusions are more common in patients with severe disease. Acute perimyocarditis has been described in a small subset of COVID-19 patients, many of whom present with cardiac tamponade.

To date, literature on biopsy and/or cytology findings in living patients with COVID-19 have been scarce, and mostly limited to case studies and small case series. Pulmonary findings on biopsy have included diffuse alveolar damage, hyaline membranes, and interstitial inflammation composed predominantly of lymphocytes. Cytology studies in COVID-19 are particularly scarce. One recent report noted plasmacytosis in a bronchoalveolar lavage specimen. Rare reports of pleural effusion specimens have generally noted reactive mesothelial cells and non-specific mixed inflammation. Autopsy studies of the lungs have generally shown diffuse alveolar damage, often with superimposed bacterial bronchopneumonia. Proposed pneumocyte viral cytopathic change including hyperplasia, multinucleation, and intranuclear inclusion bodies have been reported. Systemic findings at autopsy have included hemophagocytosis, multiple thromboemboli, endotheliitis, and tissue megakaryocyte recruitment.

SARS-CoV-2 RNA has been detected in a number of bodily fluids including bronchoalveolar fluid, sputum, feces, blood, and urine. In addition, recent single case studies have identified viral RNA in pleural and pericardial fluid, respectively, by reverse transcriptase polymerase chain reaction (RT-PCR). At this time, it is not clear whether body cavities such as the pleura or pericardium may serve as reservoirs for ongoing or repeat COVID-19 disease, or whether SARS-CoV-2 infection may be present within any of the cellular elements of effusion specimens.

To the best our knowledge, no studies have examined the specific findings in patients with COVID-19 and serous cavity effusions. The goals of our study are therefore to determine the pertinent clinical and pathologic findings in patients with COVID infection and body cavity effusions, and to determine whether effusion fluids may serve as viral reservoirs. To that end, we examined the clinical findings in a subset of our patients with confirmed SARS-CoV-2 infection and sampling of serous body effusion fluid, and determined the cytologic and fluid analytic findings seen in these effusions. This study also assessed for the presence of SARS-CoV-2 RNA within sampled cytologic material.

Materials and methods

The study was performed under approval from the University of Michigan institutional review board. An ongoing search of the University of Michigan Anatomic Pathology database (SofPathologyDx) was performed to identify cytologic cases of pleural, pericardial, or peritoneal fluids in patients who also had a positive COVID-19 nasopharyngeal PCR test from March 2020 to September 2020.

A total of 17 body cavity effusion specimens in 15 patients were identified. All cytology slides including Thinprep (Papanicolaou stained), smears (Diff-Quik stained), and sectioned cell block slides (hematoxylin and eosin stained) were retrieved from the archives along with cell block tissue cassettes. The electronic medical record was accessed to determine patient demographics (including age and sex), past medical history, history of present illness, volume of fluid collected, hospital course, and patient outcomes. In all cases, data from any concurrent fluid chemical analyses were recorded, including color, appearance, and levels of protein; pH; and glucose. Also collected were results from any associated microbiology culture findings. Finally, erythrocyte and leukocyte counts and 100 cell count differentials in these effusion samples were noted.

For comparison to pleural effusions in patients with COVID-19, we also searched our archives over a 5-year period (2016-2020) for any cases of pleural effusion with a concurrent positive test for influenza. In addition, 14 consecutive benign pleural effusion cytologies from patients with acute respiratory symptoms and pleural effusions but no established infection from November and December of 2020 were selected for microscopic review.

Cytology slides were re-reviewed by 2 cytopathologists (R.C. and L.P.) to determine the cytologic makeup of the specimens, including types of inflammatory cells present and mesothelial cell findings. The presence or absence of hemophagocytosis, megakaryocytes, and viral cytopathic changes was noted. Cell blocks were reviewed to determine adequate cellularity for in situ hybridization (ISH). ISH targeting SARS-CoV-2 spike protein transcript (V-
Table 1  Summary of patient histories and outcomes in COVID-19 patients with effusion cytology specimens.

| Patient | Age, years | Sex | Clinical history | Presenting illness/symptoms | Clinical outcome | Fluid type |
|---------|------------|-----|------------------|-----------------------------|-----------------|------------|
| 1       | 72         | M   | Diverticulitis   | Abdominal pain, bloating. No respiratory symptoms. | Died of gastroinestinal bleeding | Pleural fluid x 2 |
| 2       | 70         | M   | Cirrhosis, hepatocellular carcinoma | Dyspnea | Died of COVID-19 | Pleural fluid x 2 |
| 3       | 81         | F   | Chronic lymphocytic leukemia | Pneumonia symptoms | Died of COVID-19 | Pleural fluid |
| 4       | 67         | F   | Follicular thyroid carcinoma metastatic to lung | Altered mental status, upper respiratory symptoms | Died of COVID-19 | Pleural fluid |
| 5       | 59         | M   | No significant past medical history | Dyspnea, bilateral pneumonia on CT | Died of COVID-19 | Pleural fluid |
| 6       | 75         | M   | Chronic kidney disease, hypertension | Acute hypoxic respiratory failure | Died of COVID-19 | Pleural fluid |
| 7       | 58         | M   | Cerebrovascular accident | Altered mental status, upper respiratory symptoms | Died of COVID-19 | Pleural fluid |
| 8       | 42         | F   | Gastroesophageal reflux disease | Dyspnea, fatigue, fever | Alive | Pleural fluid |
| 9       | 49         | F   | Systemic lupus erythematosus, asthma | Prior COVID-19 hospitalization, readmitted for dyspnea after discharge | Alive | Pleural fluid |
| 10      | 76         | M   | End-stage renal disease secondary | Cough, fever, dyspnea, fatigue | Alive | Pleural fluid |
| 11      | 70         | M   | Diabetes mellitus type II, hypertension, dementia | Prior COVID-19 hospitalization, readmitted for long standing effusion | Alive | Pleural fluid |
| 12      | 37         | F   | No significant past medical history | Transferred from outside hospital with COVID-19, tamponade | Died of COVID-19 | Pericardial fluid |
| 13      | 32         | F   | No significant past medical history | Transferred from outside hospital with COVID-19, fulminant myocarditis | Alive, chest pain | Pericardial fluid |
| 14      | 35         | F   | Adnexal mass, suspected dermoid cyst | Asymptomatic, detected on pre-surgery workup | Alive | Peritoneal fluid |
| 15      | 52         | M   | Gastric carcinoma with peritoneal involvement | Acute hypoxic respiratory failure | Alive | Peritoneal fluid |
nCoV2019-S) was performed on archived cell block material in all cases with positive and negative controls (including positive and negative RNA controls on a representative cell block and a positive SARS-CoV-2 control).

**Results**

We identified 15 patients who fit study inclusion parameters, among whom a total of 17 effusion cytology specimens were collected (Table 1). There were 11 (73%) patients who had unilateral pleural effusions sampled, including 2 (13%) patients with 2 samples collected each from the same site. Two patients had pericardial effusions sampled and 2 patients had peritoneal fluid sampling (1 for ascites, 1 peritoneal washing). Patients were 32-81 years old, with 9 male and 6 female patients. Four (27%) patients had a known diagnosis of malignancy (1 gastric carcinoma, 1 hepatocellular carcinoma, 1 chronic lymphocytic leukemia, and 1 follicular thyroid carcinoma). Most (13 of 15) patients had respiratory tract symptoms ranging from dyspnea and cough to acute hypoxic respiratory failure. Of the remaining 2 patients, 1 presented with abdominal pain and bloating and the other was found to have SARS-CoV-2 incidentally on pre-surgical workup.

There were 8 of 15 (53%) patients who died during hospitalization, including 7 (47%) from COVID-related illness. There were 6 of 11 (55%) patients with pleural effusion sampling who died during the course of hospitalization, including 5 of COVID-related illness and 1 from gastrointestinal bleeding secondary to diverticular disease. One of the 2 patients with pericardial effusion died, as a result of cardiac tamponade secondary to COVID-19. Both patients with peritoneal fluid sampling are alive and were discharged.

Fluid chemical analysis was performed at the time of collection in most cases (Tables 2 and 3). Protein levels were consistently low in these effusion specimens (range, <0.8 to 5.9 g/L). The pH ranged from 6.89 to 8.15, and glucose from 19 to 150 mg/dL. Leukocyte count in these specimens ranged from 75 to 6676 cells/mL. A differential 100 cell count was performed in 14 of 17 cases. In 9 cases, lymphohistiocytic inflammation predominated, and in 5 specimens neutrophils were the predominant leukocyte present. Mesothelial cells were generally scant.

Microbiology cultures were performed in 16 of 17 specimens. Aerobic cultures showed bacterial growth in 2 (13%) cases, with 1 pleural effusion each showing growth of *Pseudomonas aeruginosa* and *Staphylococcus aureus*, respectively. Anaerobic cultures were performed in 10 cases, fungal cultures in 4 cases, and acid fast bacilli in 5 cases, with no microorganisms grown.

Cytology reports and slides were re-reviewed by 2 cytopathologists. All 17 specimens were negative for malignancy, confirmed on re-review. Lymphohistiocytic inflammation predominated in 12 of 17 cases (5

| Patient | Specimen Type | Fluid Type | Volume collected, mL | Appearance | Color | Protein, g/L | pH | Glucose, mg/dL | Aerobic cultures | Anaerobic cultures | Fungal cultures | Acid fast bacilli |
|---------|---------------|-----------|----------------------|------------|-------|--------------|----|---------------|------------------|-----------------|-----------------|-----------------|
| 1       | 1A Pleural fluid | Opaque | 500 | Red | 2.8 | 6.99 | 80 | No growth |
| 2       | 1B Pleural fluid | Cloudy | 2000 | Red | 3.7 | 8.15 | 113 | No growth |
| 3       | 2A Pleural fluid | Cloudy | 1000 | Red | 3.5 | 7.04 | 128 | No growth |
| 4       | 2B Pleural fluid | Hazy | 600 | Red | 1.7 | 7.23 | 116 | No growth |
| 5       | 3 Pleural fluid | Hazy | 400 | Orange | 1.7 | 6.89 | 38 | No growth |
| 6       | 4 Pleural fluid | Hazy | 180 | Red | 4.3 | 7.27 | 19 | No growth |
| 7       | 5 Pleural fluid | Hazy | 100 | Red | 5.1 | 7.63 | 97 | Not performed |
| 8       | 6 Pleural fluid | Hazy | 20 | Yellow | 4.2 | 7.57 | 89 | Not performed |
| 9       | 7 Pleural fluid | Hazy | 1000 | Red | 3.7 | 7.58 | 89 | Not performed |
| 10      | 8 Pleural fluid | Hazy | 1000 | Red | 4.2 | 7.57 | 89 | Not performed |
| 11      | 9 Pleural fluid | Hazy | 1000 | Red | 4.2 | 7.57 | 89 | Not performed |
| 12      | 10 Pericardial fluid | Hazy | 1000 | Red | 4.2 | 7.57 | 89 | Not performed |
| 13      | 11 Pericardial fluid | Hazy | 1000 | Red | 4.2 | 7.57 | 89 | Not performed |
| 14      | 12 Peritoneal fluid | Hazy | 1000 | Red | 4.2 | 7.57 | 89 | Not performed |
| 15      | 13 Peritoneal fluid | Hazy | 1000 | Red | 4.2 | 7.57 | 89 | Not performed |
| 16      | 14 Peritoneal fluid | Hazy | 1000 | Red | 4.2 | 7.57 | 89 | Not performed |
| 17      | 15 Peritoneal fluid | Hazy | 1000 | Red | 4.2 | 7.57 | 89 | Not performed |
lymphohistiocytic predominant, 4 histiocytic predominant, 3 lymphocytic predominant) (Table 4; Figs. 1 and 2). The remaining 5 cases included 4 with mixed acute and chronic inflammation and 1 with predominantly acute inflammation. Notably, hemophagocytosis was present in 5 (29%) cases including erythrophagocytosis in 3 specimens as well as leukophagocytosis and erythrophagocytosis in 2 cases (Fig. 3). No megakaryocytes were identified in any case. Mesothelial cells were typically scant compared with inflammatory cells, usually being present as single cells and in small clusters. Reactive mesothelial cellular changes were noted, including prominent nucleoli, but no distinct or specific pathologic changes were seen within mesothelial cells (Fig. 3). No cellular viral changes were seen, either in mesothelial cells or inflammatory cells.

Two cases of pleural effusion in patients with recent diagnosis of influenza infection were identified. Both showed lymphocytic inflammation and mesothelial cells, without hemophagocytosis. Fourteen consecutive cases of pleural effusion in patients with acute respiratory symptoms and no known infectious cause were also reviewed; 11 showed a predominance of lymphocytic or lymphohistiocytic inflammation, 2 demonstrated mixed eosinophils and lymphocytes, and 1 showed a mixture of neutrophils and lymphocytes. In all cases, hemophagocytosis was absent.

In all cases, ISH for SARS-CoV-2 was negative in all cellular elements, including mesothelial cells and inflammatory cells (Fig. 4). All ISH slides were reviewed by 2 cytopathologists (R.C. and L.P.). Appropriate positive controls were observed.

### Discussion

The signs and symptoms of COVID-19 disease are wide-ranging and may be non-specific. Though most patients present with relatively mild “flu-like” illness, approximately 10% of patients can develop more severe disease marked by lower respiratory tract involvement and/or systemic symptoms. Although only a minority of patients with SARS-CoV-2 develop body cavity effusions overall, a significant proportion of patients with severe disease will develop pleural effusions and/or pericardial effusion. One recent study found that whereas pleural effusion is rare early in the COVID-19 disease phase (2.5%), it is a relatively common occurrence in patients with more advanced-phase disease.

| Table 3 | Leukocyte counts and 100 cell count differential in COVID-associated effusions. |
|---------|---------------------------------------------------------------------------------------------------|
| Patient | Specimen     | Fluid type      | Leukocyte count, cells/mL | 100 cell count differential                                                                 |
| 1       | 1A           | Pleural fluid   | 998                       | 51% polymorphonuclear leukocytes, 21% histiocytes, 18% lymphocytes, 10% mesothelial cells    |
| 1B      | Pleural fluid | 1326            |                           | 57% polymorphonuclear leukocytes, 23% histiocytes, 20% lymphocytes                           |
| 2       | 2A           | Pleural fluid   | 360                       | 86% histiocytes, 9% lymphocytes, 4% mesothelial cells, 1% polymorphonuclear leukocytes      |
| 2B      | Pleural fluid | 75              |                           | 70% histiocytes, 22% polymorphonuclear leukocytes, 4% mesothelial cells, 4% lymphocytes    |
| 3       | Pleural fluid | 1970            |                           | 65% lymphocytes, 14% histiocytes, 13% polymorphonuclear leukocytes, 8% mesothelial cells   |
| 4       | Pleural fluid | 141             |                           | 70% lymphocytes, 14% histiocytes, 12% polymorphonuclear leukocytes, 3% mesothelial cells, 1% plasma cells |
| 5       | Pleural fluid | 2879            |                           | 80% lymphocytes, 14% histiocytes, 5% polymorphonuclear leukocytes, 1% eosinophils            |
| 6       | Pleural fluid | Not performed   |                           | 98% polymorphonuclear leukocytes, 2% lymphocytes                                            |
| 7       | Pleural fluid | 1607            |                           | 74% histiocytes, 22% lymphocytes, 4% polymorphonuclear leukocytes                           |
| 8       | Pleural fluid | Not performed   |                           | 48% histiocytes, 37% lymphocytes, 13% polymorphonuclear leukocytes, 2% mesothelial cells    |
| 9       | Pleural fluid | 6676            |                           | Not performed                                                                              |
| 10      | Pleural fluid | 499             |                           | 91% polymorphonuclear leukocytes, 5% mesothelial cells, 4% histiocytes                     |
| 11      | Pleural fluid | 1586            |                           | Not performed                                                                              |
| 12      | Pericardial fluid | 150        |                           | 91% histiocytes, 6% lymphocytes, 3% mesothelial cells                                         |
| 13      | Pericardial fluid | 397        |                           | 53% polymorphonuclear leukocytes, 33% histiocytes, 7% lymphocytes, 5% eosinophils, 2% mesothelial cells |
| 14      | Peritoneal fluid | —             |                           | 87% polymorphonuclear leukocytes, 11% lymphocytes, 2% histiocytes                           |
| 15      | Peritoneal fluid | 1062         |                           | 90% lymphocytes, 10% histiocytes                                                          |
To date, however, the pathologic features of body cavity effusions in COVID-19 patients have not been well described. In our study, the presence of a pleural effusion was an ominous finding, as 7 of 13 (54%) patients with a pleural effusion died of COVID-19 during the course of their hospitalization. This is in line with the high mortality associated with pleural effusions in the setting of acute Middle East Respiratory Syndrome, caused by a related coronavirus (MERS-CoV). Only 2 cases were identified with pericardial effusion in our study, both of whom had severe systemic and cardiac disease. One patient died of cardiac tamponade secondary to COVID-19, and the other patient has recovered from COVID-associated myocarditis with (22.7%).

Table 4  
Cytologic findings in COVID-associated body cavity effusions.

| Patient | Specimen | Fluid Type | Predominant inflammation | Mesothelial cell findings |
|---------|----------|------------|--------------------------|--------------------------|
| 1       | 1A       | Pleural fluid | Hypercellular, reactive change | Absent |
| 2       | 2A       | Pleural fluid | Hypercellular, reactive change | Absent |
| 3       | 3        | Pleural fluid | Hypercellular, reactive change | Absent |
| 4       | 4        | Pleural fluid | Lymphocytic | Scant |
| 5       | 5        | Pleural fluid | Lymphocytic | Scant |
| 6       | 6        | Pleural fluid | Lymphocytic | Scant |
| 7       | 7        | Pleural fluid | Lymphocytic | Scant |
| 8       | 8        | Pleural fluid | Lymphocytic | Scant |
| 9       | 9        | Pleural fluid | Lymphocytic | Scant |
| 10      | 10       | Pleural fluid | Lymphocytic | Scant |
| 11      | 11       | Pleural fluid | Lymphocytic | Scant |
| 12      | 12       | Pericardial fluid | Hypercellular, reactive change | Absent |
| 13      | 13       | Peritoneal fluid | Acute and chronic inflammation | Present |
| 14      | 14       | Peritoneal fluid | Acute and chronic inflammation | Present |
| 15      | 15       | Peritoneal fluid | Acute and chronic inflammation | Present |

Figure 1  
Lymphohistiocytic aggregate in a pleural fluid from an 81-year-old woman with COVID-19 pneumonia. Scattered acute inflammatory cells are also noted. (Papanicolaou stain, 400×).

Figure 2  
Pleural fluid from a 70-year-old male patient with a history of hepatocellular carcinoma, who presented with dyspnea and was diagnosed with COVID-19 pneumonia. Reactive mesothelial cell clusters surrounded by abundant histiocytes are shown, many exhibiting vacuolated cytoplasm, and admixed with scattered lymphocytes. No viral cytopathic effect was noted in any case. (Diff-Quik stain, 400×).
ongoing chest pain and dyspnea. The 2 cases of peritoneal fluid were from patients with known or suspected neoplasms, 1 with a history of pancreatic carcinoma and another with an adnexal cyst which proved to be a mature cystic teratoma on resection. Both patients are alive and without COVID-19 disease.

Fluid analysis showed that, in all COVID-19 cases, the effusions were transudative in nature (<30 g/L protein), including in both cases with aerobic bacterial growth. The latter 2 cases did show reduced glucose. The quantity of inflammatory cell involvement varied widely (75-6676 cells/mL), and in most cases lymphohistiocytic inflammation predominated. The cytologic findings were overall non-specific in nature. Mesothelial cellularity ranged from scanty and non-reactive to hypercellular and reactive. Microscopic re-examination confirmed that lymphocytic and histiocytic inflammation predominated in most cases, with only 1 case showing a predominance of neutrophils. Megakaryocytes, the presence of which has been described in biopsy and autopsy tissue from patients with COVID-19, were not detected in any case. Also absent were viral cytopathic effects.

The presence of hemophagocytosis in a subset of effusions is noteworthy. It has been hypothesized that severe cases of COVID-19 disease are linked to a cytokine storm with an associated hyperactive immune response and hemophagocytic lymphohistiocytosis. Hemophagocytosis is a common histologic finding in thoracic lymph nodes, liver, spleen, and bone marrow, and it is frequently seen at autopsy in COVID-19 patients who had clinical features of hemophagocytic syndrome such as high fever, hyperferritinemia, and cytopenias. There were 5 (29%) cases in our study that did show hemophagocytosis, being present in both pleural effusions from one patient who underwent repeat sampling. In 3 cases the only hemophagocytosis identified was of erythrocytes, and 2 cases showed hemophagocytosis of both erythrocytes and leukocytes. Interestingly, 1 of the 2 cases exhibiting phagocytosis of leukocytes was from an asymptomatic patient with an ovarian cyst who was found to be SARS-CoV-2 positive on pre-surgical workup and who did not develop symptomatic disease.

Concluding Remarks: Hemophagocytosis, the presence of which has been described in biopsy and autopsy tissue from patients with COVID-19, were not detected in any case. Also absent were viral cytopathic effects.

The presence of hemophagocytosis in a subset of effusions is noteworthy. It has been hypothesized that severe cases of COVID-19 disease are linked to a cytokine storm with an associated hyperactive immune response and hemophagocytic lymphohistiocytosis. Hemophagocytosis is a common histologic finding in thoracic lymph nodes, liver, spleen, and bone marrow, and it is frequently seen at autopsy in COVID-19 patients who had clinical features of hemophagocytic syndrome such as high fever, hyperferritinemia, and cytopenias. There were 5 (29%) cases in our study that did show hemophagocytosis, being present in both pleural effusions from one patient who underwent repeat sampling. In 3 cases the only hemophagocytosis identified was of erythrocytes, and 2 cases showed hemophagocytosis of both erythrocytes and leukocytes. Interestingly, 1 of the 2 cases exhibiting phagocytosis of leukocytes was from an asymptomatic patient with an ovarian cyst who was found to be SARS-CoV-2 positive on pre-surgical workup and who did not develop symptomatic disease. Notably, 4 patients (nos. 5, 7, 8, and 12) had clinical and laboratory findings consistent with cytokine storm, including increased serum ferritin, cytopenias, and vascular accidents, but no hemophagocytosis was identified in any of their cytology samples. In total, 2 out of 4 patients with hemophagocytosis present in effusion cytology material died of COVID-related illness and 2 are alive without evidence of disease. Thus, although hemophagocytosis is a common effusion cytology finding in patients with COVID-19, in our study it was a non-specific finding that did not correlate with severity of COVID-related disease.
It has not been established whether hemophagocytosis in effusion cytologies is more common in SARS-CoV-2 infection compared to other acute and infectious causes of pleural effusion. Pleural effusions are relatively uncommon in most forms of viral pneumonia, and indeed a search of our own archives for similar effusions in patients with a concurrent diagnosis of influenza revealed only 2 such cases in the past 5 years at our institution, both of which showed chronic lymphocytic inflammation only. Notably, both were negative for hemophagocytosis on re-review of cytologic material. In addition, re-examination of 14 recent consecutive benign pleural effusions in patients with acute respiratory symptoms and new onset pleural effusion revealed no hemophagocytosis in any case.

As noted, although radiography typically does not show pleural effusion in mild and moderate cases of COVID-19, effusions are more common in severe cases, with pleural effusion present in 59% of autopsy cases in one series. Although person-to-person spread of SARS-CoV-2 occurs primarily via respiratory droplet transmission, viral RNA has been detected in multiple body fluid types including bronchoalveolar lavage fluid, sputum, saliva, and feces. Recent individual case reports have detected SARS-CoV-2 by RT-PCR in pleural and pericardial fluids. However, it has not been established whether serous cavities may be a potential viral reservoir in advanced COVID-19 cases. Angiotensin-converting enzyme 2 (ACE2), the primary receptor of SARS-CoV-2 cellular entry, is expressed on multiple human tissue types, notably epithelium of the oral, nasal, and respiratory tracts, gastrointestinal epithelium, and endothelial cells. It is not typically expressed on inflammatory cells such as B and T lymphocytes and macrophages, however, and the potential expression of ACE2 in human mesothelial cells has not been well established.

ISH for SARS-CoV-2 was negative in all cases in our series, as no viral RNA was detected in either mesothelial or inflammatory elements within serous cavity samples. As noted previously, case reports have detected SARS-CoV-2 RNA by RT-PCR in effusion cytology specimens. However, it is not clear that such effusions harbor infectious SARS-CoV-2 viral particles or infected cellular elements.

One limitation of this study is that RT-PCR was unavailable to be performed in our samples. However, the effusions in our series were uniformly transudative by protein criteria (<30 g/L). Transudative effusions occur due to imbalances of hydrostatic and osmotic pressure such as congestive heart failure, cirrhosis, and pulmonary edema, whereas exudative effusions occur in settings of direct tissue damage. The transudative nature of the fluids and negative findings by ISH in our study suggests that although body cavity effusions were common in these advanced COVID-19 cases, they were likely secondary in nature to acute cardiopulmonary dysfunction in COVID-19 rather than direct viral-induced tissue damage.

In summary, the presence of pleural or pericardial effusion requiring clinical intervention was an ominous finding among COVID-19 patients at our institution, with 62% (8) of patients in this small series dying, including 54% (7) from COVID-related illness. The effusions in these patients were transudative in nature in all cases. Inflammation in these effusion cytology specimens was predominantly histiocytic and/or lymphocytic in most cases. Hemophagocytosis, typically a rare finding in effusion cytology specimens, is not an uncommon finding in body cavity effusion specimens from COVID-19 patients, present in 29% (5 of 17) of cases compared with 0% (0 of 16) of pleural effusions from non-COVID-19 patients in our study.

References

1. Pascarella G, Strumia A, Pliego C, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288:192–206.
2. Opoka-Winiarska V, Grywalska E, Rolinski J. Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases? BMC Med. 2020;18:214.
3. Zalehi S, Abedi A, Balakrishnan S, Gholamrezaeehnd A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol. 2020;215:87–93.
4. Bao C, Liu X, Zhang H, Li Y, Liu J. Coronavirus disease 2019 (COVID-19) CT findings: a systematic review and meta-analysis. J Am Coll Radiol. 2020;17:701–709.
5. Mohanty SK, Satapathy A, Naidu MM, et al. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)—anatomic pathology perspective on current knowledge. Diagn Pathol. 2020;15:103.
6. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [published correction appears in Lancet Respir Med. 2020 Feb 25]. Lancet Respir Med. 2020;8:420–422.
7. Flikweert AW, Grootenboers MJH, Yick DCY, et al. Late histopathologic characteristics of critically ill COVID-19 patients: different phenotypes without evidence of invasive aspergillosis, a case series [published online ahead of print, 2020 Jul 8]. J Crit Care. 2020;59:149–155.
8. Calabrese F, Pezzuto F, Fortarezza F, et al. Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European pulmonary pathologists. Virchows Arch. 2020;477:359–372.
9. Giani M, Seminati D, Lucchini A, Foti G, Pagni F. Exuberant plasmacytosis in bronchoalveolar lavage specimen of the first patient requiring extracorporeal membrane oxygenation for SARS-CoV-2 in Europe. J Thorac Oncol. 2020;15:e65–e66.
10. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323:1843–1844.
11. Mei F, Bonifazi M, Menzo S, et al. First Detection of SARS-CoV-2 by real-time reverse transcriptase-polymerase chain reaction assay in pleural fluid. Chest. 2020;158:e143–e146.
12. Farina A, Uccello G, Spreafico M, Bassanelli G, Savonitto S. SARS-CoV-2 detection in the pericardial fluid of a patient with cardiac tamponade. Eur J Intern Med. 2020;76:100–101.
13. Zhou S, Wang Y, Zhu T, Xia L. CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China. AJR Am J Roentgenol. 2020;214:1287–1294.
14. Das KM, Lee EY, Al Jawder SE, et al. Acute Middle East respiratory syndrome coronavirus: temporal lung changes observed on the chest radiographs of 55 patients. AJR Am J Roentgenol. 2015;205:W267–W274.
Cytologic findings in COVID-19 effusions

15. Vasquez-Bonilla WO, Orozco R, Argueta V, et al. A review of the main histopathological findings in coronavirus disease 2019. *Hum Pathol*. 2020;105:74–83.

16. Prilutskiy A, Kritselis M, Shevtsov A, et al. SARS-CoV-2 infection-associated hemophagocytic lymphohistiocytosis. *Am J Clin Pathol*. 2020;154:466–474.

17. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol*. 2004;203:631–637.

18. Porcel JM, Light RW. Diagnostic approach to pleural effusion in adults. *Am Fam Physician*. 2006;73:1211–1220.